Yahoo
    Tokyo - Delayed Quote JPY

    Nippon Shinyaku Co., Ltd. (4516.T)

    3,340.00 -133.00 (-3.83%)
    At close: November 6 at 3:30:00 PM GMT+9
    Loading Chart for 4516.T
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Nippon Shinyaku (TSE:4516) Stock Looks Fairly Valued At Current Levels

    Nippon Shinyaku (TSE:4516) Stock Looks Fairly Valued At Current Levels
    Simply Wall St. 20d ago
    NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO's Tadekinig alfa in the U.S.

    NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO's Tadekinig alfa in the U.S.
    PR Newswire 3mo ago
    AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa

    AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
    GlobeNewswire 3mo ago
    Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

    Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
    PR Newswire 4mo ago
    Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

    Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
    GlobeNewswire 4mo ago
    NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children's Hospital

    NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children's Hospital
    PR Newswire 4mo ago
    ADC Therapeutics Announces ZYNLONTA® Updates in Japan

    ADC Therapeutics Announces ZYNLONTA® Updates in Japan
    PR Newswire 9d ago
    Regenxbio Shares Rise After Positive Duchenne Trial Results

    Regenxbio Shares Rise After Positive Duchenne Trial Results
    InvestorsHub 5mo ago
    Capricor Lawsuit Puts Duchenne Therapy Launch Plans And Valuation In Focus

    Capricor Lawsuit Puts Duchenne Therapy Launch Plans And Valuation In Focus
    Simply Wall St. 5mo ago
    Capricor Therapeutics Q1 Earnings Call Highlights

    Capricor Therapeutics Q1 Earnings Call Highlights
    MarketBeat 5mo ago
    Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

    Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    GlobeNewswire 5mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: